Gain Therapeutics, Inc. (GANX) NASDAQ

2.40

+0.19(+8.60%)

Updated at February 05 02:09PM

Currency In USD

Gain Therapeutics, Inc.

Address

4800 Montgomery Lane

Bethesda, MD 20814

United States of America

Phone

301 500 1556

Sector

Healthcare

Industry

Biotechnology

Employees

29

First IPO Date

March 19, 2021

Key Executives

NameTitlePayYear Born
Mr. Gene Mack M.B.A.Chief Financial Officer & Interim Chief Executive Officer0N/A
Dr. Khalid Islam Ph.D.Executive Chairman75,0001955
Dr. Jonas Hannestad M.D., Ph.D.Chief Medical Officer0N/A
Dr. Joanne Taylor Ph.D.Senior Vice President of Research0N/A
Dr. Terenzio Ignoni Pharm.D.Senior Vice President of Technical Operations0N/A

Description

Gain Therapeutics, Inc., a biotechnology company, engages in developing various therapies to treat diseases caused by protein misfolding. It focuses on rare genetic diseases and neurological disorders. The company uses its Site-Directed Enzyme Enhancement Therapy platform to discover allosteric sites on misfolded proteins and identify proprietary small molecules that bind these sites, restore protein folding, and treat disease. It is developing structurally targeted allosteric regulator candidates to treat various diseases, including Morquio B, GM1 gangliosidosis (GM1), neuronopathic Gaucher disease, GBA1 Parkinson's, Krabbe, and Mucopolysaccharidosis type 1 diseases. The company was founded in 2017 and is based in Bethesda, Maryland.